Every material Form 8-K TCGX Acquisition Corp. has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TCGX Acquisition Corp., a special purpose acquisition company, signed a Business Combination Agreement on October 18, 2026 with TriGemX Bio, a company developing elismetrep for migraine. The deal would make TriGemX Bio a publicly traded company on Nasdaq under the ticker TGEM, with closing expected in the first quarter of 2027 subject to shareholder and stockholder approvals. For TCGX shareholders, the outcome depends on redemption requests, which could reduce the cash available to the combined company.
Business Combination Agreement dated October 18, 2026, among TCGX, Merger Sub and TriGemX Bio (formerly Kallyope, Inc.).
Expected gross proceeds of about $246 million before transaction costs, assuming no redemptions, including a $160 million PIPE at $10.00 per share and about $86 million from the TCGX trust account.
Pre-money equity value of TriGemX set at $361 million; post-transaction equity value expected to be about $600 million at closing, assuming no redemptions.
Closing expected in the first quarter of 2027; either party may terminate if the deal is not completed by June 30, 2027, subject to limited exceptions.
TCGX Acquisition Corp., a blank check company, closed its initial public offering on August 6, 2026, selling 8,625,000 Class A ordinary shares at $10.00 per share, including the full exercise of the underwriters' over-allotment option, for gross proceeds of $86.25 million. The full $86.25 million from the offering and private placement was deposited in a trust account, and the company has 24 months to complete a business combination or redeem the public shares.
IPO of 8,625,000 Class A ordinary shares at $10.00 per share closed August 6, 2026, for gross proceeds of $86.25 million
Private placement of 522,500 Class A ordinary shares at $10.00 per share for $5.225 million; sponsor TCGX Sponsor, LLC bought 436,250 shares and Jefferies LLC bought 86,250 shares
$86.25 million ($10.00 per public share) placed in trust account with Odyssey Transfer and Trust Company as trustee; $862,500 underwriter's discount excluded
Company has until 24 months from the IPO closing to complete a business combination, and reported $3.5 million in cash as of August 6, 2026
TCGX Acquisition Corp., a special purpose acquisition company focused on healthcare, closed its initial public offering on August 6, 2026, selling 8,625,000 Class A ordinary shares at $10.00 each for gross proceeds of $86.25 million. The filing says $86.25 million was placed in a trust account, which will not be released except for a business combination, certain shareholder redemptions, or interest used for taxes, and the company has 24 months from the IPO closing to complete a business combination. Three independent directors were appointed and two directors resigned.
Sold 8,625,000 Class A ordinary shares at $10.00 per share, including 1,125,000 shares from the full exercise of the underwriters' over-allotment option, for gross proceeds of $86.25 million.
Concurrent private placement of 522,500 shares at $10.00 per share, or $5.225 million, to the sponsor (436,250 shares) and Jefferies LLC (86,250 shares).
$86.25 million placed in a trust account at Citibank, N.A., with a 24-month deadline from the IPO closing to complete an initial business combination.
Andrew Cheng, Ying Huang and Wei Lin appointed to the board on August 4, 2026; Chen Yu and Craig Skaling resigned from the board.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TCGX Acquisition Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →